Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness

Erwin W. Gelfand, Zhi Hua Cui, Katsuyuki Takeda, Arihiko Kanehiro, Anthony Joetham

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

There is renewed interest in antihistamines for the treatment of allergic asthma. A growing body of literature has shown that the newer compounds can affect inflammatory cell accumulation and cytokine/chemokine production. In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the ability of fexofenadine to affect these outcomes was tested in a primary sensitization and challenge model and after treatment of donor mice before the adoptive transfer of T cells into recipients receiving limited allergen exposure. Mice were sensitized and challenged with allergen (ovalbumin). Airway function after inhaled methacholine was monitored in parallel to the assessment of tissue and airway inflammation and cytokine production. In further experiments, lung T lymphocytes from sensitized/challenged donor mice were transferred into naive recipients before limited airway challenge with the allergen. Administration of fexofenadine before challenge but after sensitization was effective in preventing tissue eosinophilia and airway hyperresponsiveness. Moreover, the treatment of donor mice with fexofenadine before transfer of lung T cells effectively prevented airway hyperresponsiveness and eosinophilia in naive mice exposed to limited airway challenge. These data therefore support the potential for fexofenadine in the treatment of allergen-induced airway hyperresponsiveness and inflammation.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
Volume112
Issue number4 SUPPL.
DOIs
Publication statusPublished - Oct 1 2003
Externally publishedYes

Fingerprint

fexofenadine
Allergens
Inflammation
T-Lymphocytes
Eosinophilia
Cytokines
Lung
Adoptive Transfer
Methacholine Chloride
Histamine Antagonists
Ovalbumin
Therapeutics
Chemokines
Asthma

Keywords

  • Airway hyperresponsiveness
  • Allergen
  • Antihistamines
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness. / Gelfand, Erwin W.; Cui, Zhi Hua; Takeda, Katsuyuki; Kanehiro, Arihiko; Joetham, Anthony.

In: Journal of Allergy and Clinical Immunology, Vol. 112, No. 4 SUPPL., 01.10.2003.

Research output: Contribution to journalArticle

Gelfand, Erwin W. ; Cui, Zhi Hua ; Takeda, Katsuyuki ; Kanehiro, Arihiko ; Joetham, Anthony. / Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness. In: Journal of Allergy and Clinical Immunology. 2003 ; Vol. 112, No. 4 SUPPL.
@article{a544d2c23b8a41e391fe46215d5d76ad,
title = "Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness",
abstract = "There is renewed interest in antihistamines for the treatment of allergic asthma. A growing body of literature has shown that the newer compounds can affect inflammatory cell accumulation and cytokine/chemokine production. In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the ability of fexofenadine to affect these outcomes was tested in a primary sensitization and challenge model and after treatment of donor mice before the adoptive transfer of T cells into recipients receiving limited allergen exposure. Mice were sensitized and challenged with allergen (ovalbumin). Airway function after inhaled methacholine was monitored in parallel to the assessment of tissue and airway inflammation and cytokine production. In further experiments, lung T lymphocytes from sensitized/challenged donor mice were transferred into naive recipients before limited airway challenge with the allergen. Administration of fexofenadine before challenge but after sensitization was effective in preventing tissue eosinophilia and airway hyperresponsiveness. Moreover, the treatment of donor mice with fexofenadine before transfer of lung T cells effectively prevented airway hyperresponsiveness and eosinophilia in naive mice exposed to limited airway challenge. These data therefore support the potential for fexofenadine in the treatment of allergen-induced airway hyperresponsiveness and inflammation.",
keywords = "Airway hyperresponsiveness, Allergen, Antihistamines, Inflammation",
author = "Gelfand, {Erwin W.} and Cui, {Zhi Hua} and Katsuyuki Takeda and Arihiko Kanehiro and Anthony Joetham",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0091-6749(03)01882-7",
language = "English",
volume = "112",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness

AU - Gelfand, Erwin W.

AU - Cui, Zhi Hua

AU - Takeda, Katsuyuki

AU - Kanehiro, Arihiko

AU - Joetham, Anthony

PY - 2003/10/1

Y1 - 2003/10/1

N2 - There is renewed interest in antihistamines for the treatment of allergic asthma. A growing body of literature has shown that the newer compounds can affect inflammatory cell accumulation and cytokine/chemokine production. In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the ability of fexofenadine to affect these outcomes was tested in a primary sensitization and challenge model and after treatment of donor mice before the adoptive transfer of T cells into recipients receiving limited allergen exposure. Mice were sensitized and challenged with allergen (ovalbumin). Airway function after inhaled methacholine was monitored in parallel to the assessment of tissue and airway inflammation and cytokine production. In further experiments, lung T lymphocytes from sensitized/challenged donor mice were transferred into naive recipients before limited airway challenge with the allergen. Administration of fexofenadine before challenge but after sensitization was effective in preventing tissue eosinophilia and airway hyperresponsiveness. Moreover, the treatment of donor mice with fexofenadine before transfer of lung T cells effectively prevented airway hyperresponsiveness and eosinophilia in naive mice exposed to limited airway challenge. These data therefore support the potential for fexofenadine in the treatment of allergen-induced airway hyperresponsiveness and inflammation.

AB - There is renewed interest in antihistamines for the treatment of allergic asthma. A growing body of literature has shown that the newer compounds can affect inflammatory cell accumulation and cytokine/chemokine production. In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the ability of fexofenadine to affect these outcomes was tested in a primary sensitization and challenge model and after treatment of donor mice before the adoptive transfer of T cells into recipients receiving limited allergen exposure. Mice were sensitized and challenged with allergen (ovalbumin). Airway function after inhaled methacholine was monitored in parallel to the assessment of tissue and airway inflammation and cytokine production. In further experiments, lung T lymphocytes from sensitized/challenged donor mice were transferred into naive recipients before limited airway challenge with the allergen. Administration of fexofenadine before challenge but after sensitization was effective in preventing tissue eosinophilia and airway hyperresponsiveness. Moreover, the treatment of donor mice with fexofenadine before transfer of lung T cells effectively prevented airway hyperresponsiveness and eosinophilia in naive mice exposed to limited airway challenge. These data therefore support the potential for fexofenadine in the treatment of allergen-induced airway hyperresponsiveness and inflammation.

KW - Airway hyperresponsiveness

KW - Allergen

KW - Antihistamines

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0141953286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141953286&partnerID=8YFLogxK

U2 - 10.1016/S0091-6749(03)01882-7

DO - 10.1016/S0091-6749(03)01882-7

M3 - Article

VL - 112

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4 SUPPL.

ER -